Oncoceutics, Inc. – Glioma

Access Program Information

The objective of this expanded access program is to provide ONC201 on a single patient
compassionate use basis to eligible adult subjects with recurrent glioma that exhibits a
missense histone H3 mutation .

Rare Disease: